Stroke prevention in patients with atrial fibrillation and comorbidities: evidence and common sense.
作者信息
de Groot J R
机构信息
Department of Cardiology, Heart Center, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
出版信息
Neth Heart J. 2020 Oct;28(10):501-503. doi: 10.1007/s12471-020-01491-1.
Abstract
摘要
相似文献
1
Stroke prevention in patients with atrial fibrillation and comorbidities: evidence and common sense.心房颤动合并症患者的卒中预防：证据与常识
Neth Heart J. 2020 Oct;28(10):501-503. doi: 10.1007/s12471-020-01491-1.
2
Global Prospective Safety Analysis of Rivaroxaban.全球利伐沙班安全性前瞻性分析
J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058.
3
Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective.瑞典全国视角下房颤卒中患者口服抗凝药使用情况的巨大差异
J Intern Med. 2004 Jan;255(1):22-32. doi: 10.1046/j.0954-6820.2003.01253.x.
4
Burden of comorbidities among patients with atrial fibrillation.心房颤动患者的合并症负担
Ther Adv Cardiovasc Dis. 2013 Apr;7(2):53-62. doi: 10.1177/1753944712464101. Epub 2012 Oct 22.
5
Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.年龄阈值用于非维生素 K 拮抗剂口服抗凝剂预防房颤患者卒中：深入了解最佳年龄评估和新发合并症。
Eur Heart J. 2019 May 14;40(19):1504-1514. doi: 10.1093/eurheartj/ehy837.
6
Stroke Prevention in Atrial Fibrillation: Looking Forward.心房颤动的卒中预防：展望未来。
Circulation. 2020 Dec 15;142(24):2371-2388. doi: 10.1161/CIRCULATIONAHA.120.049768. Epub 2020 Dec 14.
7
Ischemic stroke in patients with atrial fibrillation receiving oral anticoagulation.口服抗凝治疗的心房颤动患者的缺血性脑卒中。
J Neurol Sci. 2013 Nov 15;334(1-2):139-42. doi: 10.1016/j.jns.2013.08.013. Epub 2013 Aug 15.
8
Trends in utilization of antithrombotic therapy in patients with atrial fibrillation before stroke onset in a community-based study, from 1985 through 1997. From scientific evidence to practice.一项基于社区的研究中，1985年至1997年房颤患者在卒中发作前抗栓治疗的使用趋势。从科学证据到临床实践。
Prev Med. 2004 Feb;38(2):121-8. doi: 10.1016/j.ypmed.2003.09.002.
9
[Anticoagulation in vulnerable elderly patients with atrial fibrillation : risks and benefits].[老年脆弱房颤患者的抗凝治疗：风险与获益]
Rev Med Suisse. 2020 Sep 16;16(706):1718-1720.
10
Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles?老年非瓣膜性心房颤动患者预防卒中的抗凝治疗：障碍有哪些？
Hong Kong Med J. 2016 Dec;22(6):608-15. doi: 10.12809/hkmj154803.
本文引用的文献
1
New developments in adult congenital heart disease.成人先天性心脏病的新进展
Neth Heart J. 2020 Aug;28(Suppl 1):44-49. doi: 10.1007/s12471-020-01455-5.
2
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.依度沙班与维生素 K 拮抗剂在房颤患者成功经皮冠状动脉介入治疗后抗栓治疗方案的比较（ENTRUST-AF PCI）：一项随机、开放标签、3b 期临床试验。
Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3.
3
Should Every Patient With Atrial Fibrillation and a CHA2DS2-VASc Score of 1 Be Anticoagulated? A Systematic Review of 37,030 Patients.是否所有 CHA2DS2-VASc 评分为 1 分的房颤患者都应抗凝？37030 例患者的系统评价
Cardiol Rev. 2019 Sep/Oct;27(5):249-255. doi: 10.1097/CRD.0000000000000246.
4
Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis.非维生素 K 拮抗剂口服抗凝剂在老年房颤患者中的应用：系统评价与荟萃分析及试验序贯分析。
Arch Gerontol Geriatr. 2019 Mar-Apr;81:209-214. doi: 10.1016/j.archger.2018.12.013. Epub 2018 Dec 27.
5
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.2018 年欧洲心脏病学会关于非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中应用的实用指南。
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
6
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
7
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较：随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
8
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.口服抗凝治疗并行经皮冠状动脉介入治疗的患者中氯吡格雷联合或不联合阿司匹林的应用：一项开放标签、随机、对照试验。
Lancet. 2013 Mar 30;381(9872):1107-15. doi: 10.1016/S0140-6736(12)62177-1. Epub 2013 Feb 13.
9
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.荟萃分析：抗栓治疗预防非瓣膜性心房颤动患者的卒中
Ann Intern Med. 2007 Jun 19;146(12):857-67. doi: 10.7326/0003-4819-146-12-200706190-00007.
Zotero 插件